Patrick B Deegan

Summary

Affiliation: University of Cambridge
Country: UK

Publications

  1. ncbi request reprint Clinical evaluation of biomarkers in Gaucher disease
    P B Deegan
    Department of Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Acta Paediatr Suppl 94:47-50; discussion 37-8. 2005
  2. ncbi request reprint Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease
    Patrick B Deegan
    Department of Medicine, University of Cambridge, Box 157, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2QQ, UK
    Blood Cells Mol Dis 35:259-67. 2005
  3. pmc Natural history of Fabry disease in females in the Fabry Outcome Survey
    P B Deegan
    Department of Medicine, Addenbrooke s Hospital, Cambridge, CB2 2QQ, UK
    J Med Genet 43:347-52. 2006
  4. doi request reprint Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy
    Patrick B Deegan
    Lysosomal Disorders Unit, Department of Medicine, Addenbrooke s Hospital, Cambridge, United Kingdom patrick deegan addenbrookes nhs uk
    Medicine (Baltimore) 90:52-60. 2011
  5. pmc Imiglucerase in the treatment of Gaucher disease: a history and perspective
    Patrick B Deegan
    Department of Medicine, University of Cambridge, Lysosomal Disorders Unit, Addenbrooke s NHS Foundation Hospitals Trust, Cambridge, UK
    Drug Des Devel Ther 6:81-106. 2012
  6. doi request reprint Potential biomarkers of osteonecrosis in Gaucher disease
    Elena V Pavlova
    Department of Medicine, University of Cambridge, UK
    Blood Cells Mol Dis 46:27-33. 2011
  7. doi request reprint Biomarkers for osteonecrosis in Gaucher disease
    Elena V Pavlova
    University of Cambridge, Addenbrroke s Hospital, Department of Medicine, Lysosomal Disorders Unit Box 135, Cambridge, UK
    Expert Opin Med Diagn 6:1-13. 2012
  8. doi request reprint Fabry disease, enzyme replacement therapy and the significance of antibody responses
    Patrick B Deegan
    Department of Medicine, Addenbrooke s Hospital, Cambridge, CB2 2QQ, UK
    J Inherit Metab Dis 35:227-43. 2012

Detail Information

Publications8

  1. ncbi request reprint Clinical evaluation of biomarkers in Gaucher disease
    P B Deegan
    Department of Medicine, University of Cambridge, Addenbrooke s Hospital, Cambridge, UK
    Acta Paediatr Suppl 94:47-50; discussion 37-8. 2005
    ....
  2. ncbi request reprint Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease
    Patrick B Deegan
    Department of Medicine, University of Cambridge, Box 157, Addenbrooke s Hospital, Hills Road, Cambridge CB2 2QQ, UK
    Blood Cells Mol Dis 35:259-67. 2005
    ..To improve the assessment of severity of disease and responses to this costly treatment, we have evaluated several enzymatic biomarkers and a newly-described chemokine...
  3. pmc Natural history of Fabry disease in females in the Fabry Outcome Survey
    P B Deegan
    Department of Medicine, Addenbrooke s Hospital, Cambridge, CB2 2QQ, UK
    J Med Genet 43:347-52. 2006
    ..Although the severity of clinical features in male patients is well described, only recently have studies reported the high prevalence of disabling clinical features in heterozygous females...
  4. doi request reprint Osseous manifestations of adult Gaucher disease in the era of enzyme replacement therapy
    Patrick B Deegan
    Lysosomal Disorders Unit, Department of Medicine, Addenbrooke s Hospital, Cambridge, United Kingdom patrick deegan addenbrookes nhs uk
    Medicine (Baltimore) 90:52-60. 2011
    ..The relationship between clinical and biochemical markers and existing bone complications sets the scene for future prospective studies that will focus on management strategies informed by credible assessment of risk...
  5. pmc Imiglucerase in the treatment of Gaucher disease: a history and perspective
    Patrick B Deegan
    Department of Medicine, University of Cambridge, Lysosomal Disorders Unit, Addenbrooke s NHS Foundation Hospitals Trust, Cambridge, UK
    Drug Des Devel Ther 6:81-106. 2012
    ..The fortunes of the Genzyme Corporation, latterly acquired by global giant Sanofi SA, were founded on the evolution of a blockbuster therapy for a single but, as it turns out, propitious ultra-orphan disorder: Gaucher disease...
  6. doi request reprint Potential biomarkers of osteonecrosis in Gaucher disease
    Elena V Pavlova
    Department of Medicine, University of Cambridge, UK
    Blood Cells Mol Dis 46:27-33. 2011
    ..To investigate the relationship between chemokines and cytokines and osteonecrosis in Gaucher disease, we conducted multiplex assays in a cohort of 100 adult patients...
  7. doi request reprint Biomarkers for osteonecrosis in Gaucher disease
    Elena V Pavlova
    University of Cambridge, Addenbrroke s Hospital, Department of Medicine, Lysosomal Disorders Unit Box 135, Cambridge, UK
    Expert Opin Med Diagn 6:1-13. 2012
    ..Ultimately, exploration of this field will provide the basis for a refined mechanistic understanding of pathogenesis...
  8. doi request reprint Fabry disease, enzyme replacement therapy and the significance of antibody responses
    Patrick B Deegan
    Department of Medicine, Addenbrooke s Hospital, Cambridge, CB2 2QQ, UK
    J Inherit Metab Dis 35:227-43. 2012
    ..Further studies that examine the development of antibodies in patients with Fabry disease and the potential impact of such antibodies on the outcome of ERT are necessary...